A new vaginal ring technology, the insert vaginal ring (InVR), is presented. The InVR overcomes the current shortfall of conventional vaginal rings (VRs) that are generally ineffectual for the delivery of hydrophilic and/or macromolecular actives, including peptides, proteins and antibodies, due to their poor permeation characteristics in the hydrophobic polymeric elastomers from which VRs are usually fabricated. Release of the model protein BSA from a variety of insert matrices for the InVR is demonstrated, including modified silicone rods, directly compressed tablets and lyophilised gels, which collectively provided controlled release profiles from several hours to beyond 4 weeks. Furthermore, the InVR was shown to deliver over 1 mg of the monoclonal antibody 2F5 from a single device, offering a potential means of protecting women against the transmission of HIV.
|Journal||European Journal of Pharmaceutics and Biopharmaceutics|
|Publication status||Published - 2011|
Morrow, R. J., Woolfson, A. D., Donnelly, L., Curran, R. M., Andrews, G. P., Katinger, D., & Malcolm, R. K. (2011). Sustained release of proteins from a modified vaginal ring device. European Journal of Pharmaceutics and Biopharmaceutics, 77, 3-10. https://doi.org/10.1016/j.ejpb.2010.10.010